PT  - JOURNAL ARTICLE
AU  - Lederman, Lynne
ED  - Weir, Matthew R.
TI  - Patiromer Controls RAASi-Associated HK in Patients with Diabetes and CKD
DP  - 2015 Feb 01
TA  - MD Conference Express
PG  - 13--14
VI  - 14
IP  - 49
4099  - http://mdc.sagepub.com/content/14/49/13.short
4100  - http://mdc.sagepub.com/content/14/49/13.full
AB  - Renin-angiotensin-aldosterone system inhibitors (RAASis) are beneficial and recommended for patients with chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). However, hyperkalemia (HK) often limits RAASi therapy. The OPAL-HK [NCT01810939] trial found that patiromer normalized serum potassium (s-K+) and prevent HK recurrence compared with placebo. This article discusses a poster investigating the prespecified analysis of the subgroup with T2DM in OPAL-HK.